MedTrace Logo

Post-market Multi-Center RETRO-Prospective Study to Assess Long-term Clinical Outcomes NMSC Patients Treated With eBx

NCT05257486 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 183

Last updated 2025-01-13

Study results available
· View outcomes & findings →

Summary

The purpose of this retrospective-prospective study is to evaluate lesions after treatment for BCC or SCC NMSC in order to gain a better understanding of the durability of the treatment, and risk of late toxicities for this patient population.

Conditions

  • Non-melanoma Skin Cancer

Interventions

DEVICE

Xoft eBx

The Xoft Axxent Electronic Brachytherapy (eBx) System allows for the administration of high dose rate brachytherapy treatments using an electronic source

Sponsors & Collaborators

  • Xoft, Inc.

    lead INDUSTRY

Principal Investigators

  • Stephen Doggett, MD · Mission Health

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-09
Primary Completion
2022-07-18
Completion
2022-10-13
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05257486 on ClinicalTrials.gov